Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity

研究成果: Article同行評審

9 引文 斯高帕斯(Scopus)

摘要

Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses were stable and similar. The dose, procedure, and premedication were the same; however, twin B presented with hypotension for 3 days. Although bevacizumab-related hypotension has been described in product information (incidence rate 7%-15%), this is the first case report of intravitreal bevacizumab for ROP inducing hypotension. Physicians should be aware of intravitreal bevacizumab therapy-related hypotension when treating ROP. We suggest conducting a postmarketing active surveillance on the systemic adverse effects of this regimen in preterm infants.

原文English
文章編號e20152005
期刊Pediatrics
137
發行號2
DOIs
出版狀態Published - 2016 二月

All Science Journal Classification (ASJC) codes

  • 兒科、圍產兒和兒童健康

指紋

深入研究「Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity」主題。共同形成了獨特的指紋。

引用此